HopeStage
Back to all studies
CompletedNCT05693935

TV-44749 safety and effectiveness in adults with schizophrenia

About this titleRead the official source — NCT05693935

Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

Medication studyAges 18–64Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Listed locations
Bentonville and 81 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 24, 2023
Recruitment status
Completed
Enrollment listed in the registry
675
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, China, ...
Age range
From 18 Years to 64 Years
Official registry ID
NCT05693935
Official title
Show the full official title

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bentonville, United States · Little Rock, United States · Rogers, United States

65 more locations
  • Anaheim, United States
  • Bellflower, United States
  • Garden Grove, United States
  • La Habra, United States
  • Lemon Grove, United States
  • Long Beach, United States
  • Los Angeles, United States
  • Orange, United States
  • Pico Rivera, United States
  • Riverside, United States
  • San Diego, United States
  • Santee, United States
  • Sherman Oaks, United States
  • Torrance, United States
  • Hialeah, United States
  • Hollywood, United States
  • Homestead, United States
  • Miami, United States
  • Miami Lakes, United States
  • Miami Springs, United States
  • West Palm Beach, United States
  • Atlanta, United States
  • Decatur, United States
  • Peachtree Corners, United States
  • Chicago, United States
  • Shreveport, United States
  • Gaithersburg, United States
  • Flowood, United States
  • St Louis, United States
  • Marlton, United States
  • Charlotte, United States
  • Dayton, United States
  • North Canton, United States
  • Oklahoma City, United States
  • Austin, United States
  • DeSoto, United States
  • Irving, United States
  • Richardson, United States
  • Burgas, Bulgaria
  • Kazanlak, Bulgaria
  • Lovech, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Razgrad, Bulgaria
  • Rousse, Bulgaria
  • Sliven, Bulgaria
  • Sofia, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Beijing, China
  • Hangzhou, China
  • Hefei, China
  • Jining Shi, China
  • Nanchang, China
  • Shanghai, China
  • Tianjin, China
  • Wuhan, China
  • Xinxiang, China
  • Zhumadian, China
  • Bucharest, Romania
  • Iași, Romania
  • Adapazarı, Türkiye
  • Ankara, Türkiye
  • Bursa, Türkiye
  • Türkiye

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared TV-44749 and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

Who is behind this study?

The study sponsor is Teva Branded Pharmaceutical Products R&D LLC, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including TV-44749 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies